Collection of data and samples from adults with suspected inflammatory myopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study involves a prospective cohort of adult patients who have a clinical suspicion of idiopathic inflammatory myopathy. Participants will provide longitudinal clinical data and biological samples, including blood, urine, stool, and muscle specimens. The aim is to create a comprehensive database that can aid in understanding and treating these conditions more effectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical suspicion of Adult Inflammatory Myopathy
* Social security affiliation

Exclusion Criteria:

* Pregnant and lactating women
* Patients unable to consent
* Patients refusing to participate in the research.
* Patients under legal protection

Where it's running

• CHU de BREST
  Brest, France Recruiting

Study contacts

• Study coordinator: Dewi GUELLEC
• Email: dewi.guellec@chu-brest.fr
• Phone: 0230337617

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MTS109 treatment for refractory autoimmune diseases

  This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07526350

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's

  This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.

  Recruiting Phase 1 Xencor, Inc. · Melbourne · NCT07284797

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

  This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT07022197

• Investigating AZD5492 for treating systemic lupus erythematosus and inflammatory myopathies

  This study is testing a new medication called AZD5492 to see if it can safely help adults with systemic lupus erythematosus and inflammatory myopathies feel better.

  Recruiting at 33 sites Phase 1 AstraZeneca · Anniston, Alabama and 37 other locations · NCT06916806

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.